No black box warning on record for Symtuza

As of the latest FDA labeling reviewed, Symtuza (DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Symtuza medicine page for the complete safety profile.

Other warnings & precautions

5. WARNINGS AND PRECAUTIONS Drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) including some fatalities can occur with SYMTUZA. Monitor liver function before and during therapy, especially in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases. ( 5.2 ) Severe skin reactions, including Stevens-Johnson syndrome, t

No black box warning on record for Symtuza

Other warnings & precautions

5. WARNINGS AND PRECAUTIONS Drug-induced hepatitis (e.g., acute hepatitis, cytolytic hepatitis) including some fatalities can occur with SYMTUZA. Monitor liver function before and during therapy, especially in patients with underlying chronic hepatitis, cirrhosis, or in patients who have pre-treatment elevations of transaminases. ( 5.2 ) Severe skin reactions, including Stevens-Johnson syndrome, t

Symtuza Black Box Warning

No black box warning on record for Symtuza

Other warnings & precautions

Symtuza Black Box Warning

No black box warning on record for Symtuza

Other warnings & precautions